Celgene Corporation (NASDAQ:CELG) closed its last session at $103.11. The stock traded within a range of $102.71 and $105.33. The company operates in the Healthcare sector with a market capitalization of 80.44 Million. Trading volume for Celgene Corporation was 8.67 Million in its previous trading session. Currently, Celgene Corporation (NASDAQ:CELG) has an average volume of 8.42 Million.
Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options. There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma. In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis. The company’s major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients.
Celgene Corporation (NASDAQ:CELG) received a Buy rating from 6 analysts. 1 analysts gave its stock an Outperform rating. 3 analysts say it’s a Hold while 0 analysts provided their expert opinion as Sell.
Celgene Corporation (NASDAQ:CELG) touched its 1-Year High price of $147
.17 on 10/02/17 and its 1-Year Low price of $ 94.55 on 10/26/17.
EPS & Financials
Celgene Corporation (NASDAQ:CELG) reported its EPS in the last quarter as $1.91/Share beating the analyst estimate of $1.87/Share by a difference of $0.04. This showed a surprise of 2.1% in the last quarter earnings.
For the current quarter, 28 analysts are projecting a mean EPS of $1.97/share. According to their observations and findings, the stock could provide a high EPS of $2.06/share and a low EPS of $1.87/share.
Analysts believe that the company has the potential to earn average revenue of $3.47 Billion for the current quarter. According to their predictions high & low revenue estimates are 3.62 Billion and 3.34 Billion respectively.
By taking a look at the stock’s current statistics it can gauged that the stock candle is BEARISH with MEDIUM volatility. Celgene Corporation (NASDAQ:CELG) has a 20-Day average volume of 7.71 Million. According to today’s trading volume Celgene Corporation is ABOVE its 20-Day Avg. volume with the stock showing ABOVE Abnormal volume in the past 150 days.
Moving average convergence divergence (MACD) shows that the stock is on a PRICE RELATIVITY trend. The trend for the past 10-days shows that the company was in BEARISH territory while an analysis of the last 40-Day trend shows a BULLISH signal. The 100-Day trend also shows a BEARISH trend as well.
The company currently has an insider ownership of 0.2 Percent and Institutional ownership of 82 Percent. The return on assets stands at 13.3%, Return on Equity currently is 48.7% and the Return on Investment value is 11.7%.
Celgene Corporation (NASDAQ:CELG) gross margin percentage stands at 96.4% while its operating margin for the past trailing twelve month is 36.5 percent and its overall profit margin (ttm) is 31.7 Percent. The stock is currently moving below its 20-Day Simple Moving Average of -1.72% with a 50-Day Simple Moving Average of -1.46 percent. As of today, the company has a SMA200 (200-day simple moving average) of -15.77 Percent. The Stock has YTD (year to date) performance of -1.2 percent.
The TTM operating margin for the company stands at 36.5%. The return on invested capital is at 11.7%, which is good, compared to its peers. The Free Cash Flow or FCF margin is 19.28.
The company’s stock is currently moving with a -ve distance from the 200 day SMA of approximately -15.77%, and has a solid year to date (YTD) performance of -1.2% which means that the stock is constantly adding to its value from the previous fiscal year end price.